Resonant Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$857K Sell
1,726
-50
-3% -$22.2K 0.04% 208
2026
Q1
$793K Buy
1,776
+210
+13% +$97.9K 0.04% 201
2025
Q4
$710K Buy
1,566
+102
+7% +$44K 0.04% 201
2025
Q3
$573K Sell
1,464
-94
-6% -$39.3K 0.03% 229
2025
Q2
$694K Buy
1,558
+108
+7% +$49.8K 0.04% 199
2025
Q1
$703K Buy
1,450
+183
+14% +$85.3K 0.05% 174
2024
Q4
$510K Buy
1,267
+41
+3% +$19K 0.04% 204
2024
Q3
$570K Buy
1,226
+145
+13% +$69.7K 0.04% 202
2024
Q2
$507K Buy
1,081
+276
+34% +$120K 0.04% 203
2024
Q1
$336K Buy
+805
New +$340K 0.03% 250

Other funds holding VRTX

Resonant Capital Advisors's VRTX Position: Q2 2026 in Review

Resonant Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q2 2026, selling an estimated $22.2K and leaving 1,726 shares worth $857K. The position accounts for 0.04% of the portfolio, ranked #208.

Resonant Capital Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Resonant Capital Advisors held 1,726 shares of Vertex Pharmaceuticals worth $857K as of Q2 2026.
  • Resonant Capital Advisors sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
  • Vertex Pharmaceuticals made up 0.04% of Resonant Capital Advisors's portfolio in Q2 2026, its #208 holding.
  • Resonant Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Resonant Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.